Table 2.

Pearson Correlation Between Prescription of Antifungal Agents (Defined Daily Dose per 1000 Patient Days) and Isolation of Candida Species (per 1000 Patient Days) Within the Same Quarter in the Healthcare Network in Hong Kong.^a,b

Healthcare Network	Pearson Correlation for all Candida Species (95% Confidence Interval)	p value	Pearson Correlation for Candida Albicans (95% Confidence Interval)	p value
Network A	0.699 (0.473–0.839)	<0.001	0.634 (0.376–0.800)	<0.001
Network B	0.503 (0.199–0.719)	0.002	0.678 (0.441–0.827)	<0.001
Network C	0.869 (0.752–0.933)	<0.001	0.600 (0.329–0.780)	<0.001
Network D	0.791 (0.619–0.891)	<0.001	0.637 (0.380–0.802)	<0.001
Network E	0.308 (−0.033–0.586)	0.076	−0.125 (−0.444–0.223)	0.482
Network Fc	−0.128 (−0.447–0.220)	0.471	−0.602 (−0.781 – −0.331)	<0.001
Network Gc	0.850 (0.718–0.923)	0.001	0.871 (0.756–0.934)	<0.001
Overall (Network A to G)	0.886 (0.782–0.942)	<0.001	0.760 (0.568–0.874)	<0.001

Notes: ^aThe isolation of Candida species is expressed as the number of unique Candida species per 1000 patient days. A unique Candida species refers to a non-duplicated isolate of the first Candida species identified during the same episode of hospitalization throughout the study period from 2015 1Q to 2023 2Q. ^bThe antifungal agents includes amphotericin B (parenteral), echinocandin [anidulafungin (parenteral), caspofungin (parenteral), micafungin (parenteral)], triazole [fluconazole (oral and parenteral), isavuconazole (oral and parenteral), itraconazole (oral and parenteral), posaconazole (oral and parenteral), voriconazole (oral and parenteral)], and others [5-flucytosine (oral and parenteral), griseofulvin (oral), ketoconazole (oral), miconazole (parenteral), nystatin (oral), terbinafine (oral)]. ^cHealthcare network with nosocomial outbreaks of C. auris.